Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma
Retrieved on:
Tuesday, December 28, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Thought, EZH2, ADC, Quality of life, Daiichi Sankyo, Patient, Peripheral T-cell lymphoma, Paced Auditory Serial Addition Test, DXD, ORR, Cancer, ODD, Incidence, Survival, ATL, Program, Progression-free survival, Research, Alpha, Death, ASH, Adult, Ministry of Health, Labour and Welfare, Technology, Health care system in Japan, EZH1, Laboratory, Society, Cardiovascular disease, NHL, Safety, Orphan drug, Doctor of Philosophy, NDA, PTCL, MHLW, Central, Sustainable development, Prognosis, Pharmaceutical industry, Fine chemical, Health, Limited, Adult T-Cell Leukemia/Lymphoma, Valemetostat, the Pivotal Phase 2 Study, Daiichi Sankyo, ADULT T-CELL LEUKEMIA/LYMPHOMA, VALEMETOSTAT, THE PIVOTAL PHASE 2 STUDY, DAIICHI SANKYO
Valemetostat previously received Orphan Drug designation (ODD) from the Japan MHLW for treatment of patients with relapsed/refractory ATL.
Key Points:
- Valemetostat previously received Orphan Drug designation (ODD) from the Japan MHLW for treatment of patients with relapsed/refractory ATL.
- Valemetostat is the fifth innovative oncology medicine from our pipeline to be submitted for regulatory approval in Japan in the past three years.
- Valemetostat received ODD from the U.S. Food & Drug Administration for the treatment of PTCL in December 2021, ODD from the Japan MHLW for the treatment of relapsed/refractory ATL in November 2021 and SAKIGAKE Designation from the Japan MHLW for the treatment of adult patients with relapsed/refractory PTCL in April 2019.
- A total of 25 patients were enrolled in the study in Japan.